French antibody biotech Adcytherix secured €105 million (roughly $122 million) in a Series A to move its lead ADC program into clinical development next year. The financing aims to support IND‑enabling studies, manufacturing and the planned first‑in‑human trial, accelerating a year‑and‑a‑half‑old company toward the clinic. Adcytherix’s strategy centers on proprietary antibody and payload chemistry for targeted cytotoxic delivery. The round signals continued investor confidence in ADCs as modular oncology platforms despite competition across the class.